GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » Loans Receivable

IDEAYA Biosciences (FRA:30J) Loans Receivable : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Loans Receivable?

IDEAYA Biosciences's Loans Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.


IDEAYA Biosciences Loans Receivable Historical Data

The historical data trend for IDEAYA Biosciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Loans Receivable Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

IDEAYA Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IDEAYA Biosciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


IDEAYA Biosciences Loans Receivable Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEAYA Biosciences Business Description

Traded in Other Exchanges
Address
7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

IDEAYA Biosciences Headlines

No Headlines